久久www免费人成精品,国产伊人色噜噜综合网,99久久久无码国产精品免费

溴沙定

NMR下載 COA and HPLC MSDS下載
names：
Broxaldine
CAS號：
3684-46-6
MDL Number：
MF(分子式)： C17H11Br2NO2 MW(分子量)： 421.08
EINECS:222-971-1 Reaxys Number:
Pubchem ID:77262 Brand:BIOFOUNT

溴沙定(3684-46-6,Broxaldine,Brobenzoxaldine)是一種抗原蟲藥。Broxaldine抑制艱難梭菌的MIC值為4 µM，并具有抗真菌作用。

貨品編碼	規(guī)格	純度	價格 (￥)	現(xiàn)價(￥)	特價(￥)	庫存描述	數(shù)量	總計 (￥)
YZM000784-50mg	50mg	>98.0%	￥ 0.00	￥ 0.00		Backorder	- +	￥ 0.00
YZM000784-10mg	10mg	>98.0%	￥ 487.50	￥ 487.50		2-3天	- +	￥ 0.00

大包裝詢價提供各種包裝，敬請垂詢
收藏商品商品點評加入購物車立即購買

快速詢價

收起

你想詢價的產(chǎn)品

*產(chǎn)品名稱：

CAS號：

產(chǎn)品編號：

需求描述：

請準確填寫您的聯(lián)系方式，以便為您提供最好的服務(wù)。

*公司名稱：

*電子郵箱：

聯(lián)系人：

*電話：

*驗證碼：

詢價

中文別名	溴沙定(3684-46-6);溴索丁;二溴甲喹苯酯;5,7-二溴-2-甲基-8-喹啉基苯甲酸酯;5,7-二溴-8-羥基喹那啶;5,7-二溴-8-苯甲酰氧基奎尼丁; 5,7-二溴-2-甲基-8-酚基苯甲酸酯；
英文別名	Broxaldine(3684-46-6);5,7-dibromo-2-methyl-8-quinolylbenzoate;Broxaldine;Brobenzoxaldine; 5,7-Dibromo-8-benzoyloxyquinaldine; 5,7-Dibrom-2-methyl-8-chinolyl benzoat;
CAS號	3684-46-6
Inchi	InChI=1S/C17H11Br2NO2/c1-10-7-8-12-13(18)9-14(19)16(15(12)20-10)22-17(21)11-5-3-2-4-6-11/h2-9H,1H3
InchiKey	IJTPLVAAROHGGB-UHFFFAOYSA-N
分子式 Formula	C17H11Br2NO2
分子量 Molecular Weight	421.08
溶解度Solubility	生物體外In Vitro:DMSO溶解度≥ 42.86 mg/mL(101.79 mM)*"≥" means soluble可溶, but saturation unknown溶解度未知.
性狀	固體粉末,Power
儲藏條件 Storage conditions	-20°C 3 years年 4°C 2 years年 / In solvent溶液中:-80°C 6 months月 -20°C 1 month月

溴沙定(3684-46-6,Broxaldine,Brobenzoxaldine)實驗注意事項：
1.實驗前需戴好防護眼鏡，穿戴防護服和口罩，佩戴手套，避免與皮膚接觸。
2.實驗過程中如遇到有毒或者刺激性物質(zhì)及有害物質(zhì)產(chǎn)生，必要時實驗操作需要手套箱內(nèi)完成以免對實驗人員造成傷害
3.實驗后產(chǎn)生的廢棄物需分類存儲，并交于專業(yè)生物廢氣物處理公司處理，以免造成環(huán)境污染Experimental considerations:
1. Wear protective glasses, protective clothing and masks, gloves, and avoid contact with the skin during the experiment.
2. The waste generated after the experiment needs to be stored separately, and handed over to a professional biological waste gas treatment company to avoid environmental pollution.

Tags:溴沙定試劑,溴沙定雜質(zhì),溴沙定合成,溴沙定中間體,溴沙定密度,溴沙定溶解度,溴沙定旋光度,溴沙定閃點,溴沙定熔點,溴沙定購買,

產(chǎn)品說明	溴沙定(3684-46-6,Broxaldine,Brobenzoxaldine)是一種抗原生動物藥物。
Introduction	溴沙定(3684-46-6,Broxaldine,Brobenzoxaldine)is an antiprotozoal drug.
Application1
Application2
Application3

溴沙定(3684-46-6,Broxaldine,Brobenzoxaldine)藥理學(xué)：

溴沙定(3684-46-6,Broxaldine,Brobenzoxaldine)是一種抗原蟲藥。Broxaldine抑制艱難梭菌的MIC值為4 µM，并具有抗真菌作用。

警示圖
危險性	warning
危險性警示	Not available
安全聲明	H303吞入可能有害+H313皮膚接觸可能有害+H2413吸入可能對身體有害
安全防護	P264處理后徹底清洗+P280戴防護手套/穿防護服/戴防護眼罩/戴防護面具+P305如果進入眼睛+P351用水小心沖洗幾分鐘+P338取出隱形眼鏡（如果有）并且易于操作,繼續(xù)沖洗+P337如果眼睛刺激持續(xù)+P2393獲得醫(yī)療建議/護理
備注	實驗過程中防止吸入、食入，做好安全防護

Hazra SK, et al. Therapeutic trial of a combination of broxyquinoline and brobenzoxaldine in the treatment of leprosy. Lepr India. 1979 Oct;51(4):505-10.

AbdelKhalek A, et al. Screening for potent and selective anticlostridial leads among FDA-approved drugs. J Antibiot (Tokyo). 2020 Mar 4.

A study on the neurotoxicity of broxyquinoline and brobenzoxaldine combination in therapeutic doses PMID 3081428; Human toxicology 1986 Jan; 5(1):35-41 Name matches: broxyquinoline brobenzoxaldine

Impairment of exercise tolerance due to broxyquinoline-brobenzoxaldine combination PMID 3081430; Human toxicology 1986 Jan; 5(1):63-4 Name matches: broxyquinoline brobenzoxaldine

Broxyquinoline and brobenzoxalidine suspension (Intestopan-AI 307) in childhood diarrhoea. A clinical trial on 533 children PMID 4933138; Indian journal of pediatrics 1970 May; 37(268):177-84 Name mat

溴沙定(3684-46-6,Broxaldine,Brobenzoxaldine)參考文獻：

1.[Toxicity of hydroxyquinoline derivatives].
Pashov D, Simeonov SP, Drumev D, Pe?nikova Ts, Dzhurov A. Vet Med Nauki. 1980;17(3):118-23.

We studied a 90 day toxicity in dogs of the compound broxyquinoline + broxaldine--5:1 (enteroquin), applied orally and daily in doses of 0.1 and 0.2/kg t/24 h. We established the toxic manifestations during the period after the 15th day of the treatment: leukopenia, neutropenia and lymphocytosis (by 0.2 kg t/24 h). After the second and fifth day we observed a decrease of appetite, depression of the CNS, paralyses, arrhythmia, progressing loss in weight, proteinorrhea (more pronounced with those receiving 0.2/kg t (24 h); lethal consequence with some part of the animals 25% (ba 0.1/kg t) and 50% (by 0.2 kg t). We found out pathohistologically necrobiotic changes in the medulla oblongata and the kidneys, toxic distrophy of the liver, blood-vessel injuries. The toxic changes observed can be interpreted in connection with the presence of a species specific reaction.

2.Letter: Effect of broxyquinoline and broxaldine in leprosy.
Sharma CS. Lancet. 1975 Feb 15;1(7903):405.

3、A study on the neurotoxicity of broxyquinoline and brobenzoxaldine combination in therapeutic doses
R Swain, J S Bapna, A K Das, S Chandrasekar, R P Swaminathan, B Bosco, S Veliath, D P Thombre

Abstract The neurotoxicity of a combination of broxyquinoline and brobenzoxaldine (Intestopan Forte, containing 500 mg and 100 mg of the drugs respectively per capsule) was investigated by prospective clinical and electrophysiological studies in patients and volunteer subjects given the drugs in therapeutic doses (two capsules three times a day for 5 days). Of 16 patients with intestinal amoebiasis given the drugs (study A), 13 (81.25%) were cured. Adverse effects were mild and did not affect treatment. No neurological adverse effect was reported. Neurological examinations revealed no abnormality in any patient after treatment. Seven volunteer subjects underwent medical, neurological and ophthalmological examinations, and electrophysiological studies of ulnar and peroneal nerve conduction before and after treatment with the drugs in therapeutic doses (study B). Transient paresthesias were reported by one subject on the fourth day of treatment. No medical, neurological or ophthalmological abnormality was detected in any subject after treatment. There was no significant change in motor nerve conduction velocities. There was a significant (P less than 0.001) increase in the stimulus strength for distal ulnar stimulation and a significant (P less than 0.01) decrease in stimulus duration for proximal and distal ulnar stimulation. No significant changes were seen in the peroneal nerves in these parameters. No qualitative abnormality was seen in the oscilloscopic patterns of nerve conduction after treatment. Literature on the neurotoxicity of the halogenated hydroxyquinolines is reviewed. It is concluded that broxyquinoline and brobenzoxaldine (and probably other halogenated hydroxyquinolines as well) are safe and effective in therapeutic doses; neurotoxicity is unlikely to occur when these drugs are used according to therapeutic recommendations.

對不起，暫無產(chǎn)品評價！

MSDS

SDS 1.0 中文

展開

SDS 1.0 英文

展開